A Medical Device Daily
Quick-Med Technologies (Gainesville, Florida) said that the U.S. Patent and Trademark Office (USPTO) issued U.S. patent No. 7,473,474 to Quick-Med covering select uses of the NIMBUS technology.
This patent stems from a provisional patent application filed with the USPTO in February 2004 by Quick-Med. The new patent, together with a previously issued patent and eleven additional pending patent applications plus foreign counterparts pending in Europe, Australia, Brazil, Canada, China, India, Japan, Mexico, and South Africa, provide broad coverage for NIMBUS, an innovative, next-generation antimicrobial technology.
What makes NIMBUS different from other antimicrobial technology, according to the company, are its permanent bond and its ability to be effective even in the presence of large amounts of body fluids which can "blind" other antimicrobials.